A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Inclusion Criteria:
Exclusion Criteria:
Lyon - Pierre Benite, France 69495, France
Brescia, 25123, Italy
Banská Bystrica, Slovak Republic 975 17, Slovakia
Nitra Stare Mesto, Slovak Republic 949 01, Slovakia
Waltham, Waltham Forest E11 1NR, United Kingdom